# Radium-223 in Biochemically Recurrent Prostate Cancer

> **NCT04206319** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Biochemical Recurrent Prostate Cancer

## Interventions

- **DRUG:** Radium-223
- **DRUG:** 18F Sodium Fluoride

## Key facts

- **NCT ID:** NCT04206319
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-22
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-07-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04206319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04206319, "Radium-223 in Biochemically Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04206319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*